

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Pasadena, CA – April 9, 2022

Conference
Location

Hilton Pasadena
168 South Los Robles Avenue
Pasadena, CA

Phone: (626) 577-1000

<https://www.hilton.com/en/hotels/pasphhf-hilton-pasadena/>

Parking at the
Conference

Reduced parking for all participants is available for \$12. Street parking and nearby lots are also available.

From US-101 S/(Ventura Fwy) OR US 5 (Golden State Fwy) and CA-134 E (Pasadena Fwy):

Driving
Directions

- Continue on CA-134 E, follow signs for Burbank/Pasadena.
- Take exit 25C to Corson Street
- Merge onto Corson Street and turn south (right) at South Las Robles Avenue
- The hotel will be on the left side just before Cordova St

Seminar Agenda
and Syllabus
Information

Registration begins at **7:00am** in the San Gabriel Room. Please check signage for any last-minute room changes.

The Hepatitis and Chronic Liver Disease seminar is a paperless program. The **course syllabus and related materials will be made available on a digital app** that can be accessed by a smart phone, tablet or personal computer. Instructions to download the *App* will be provided. Wi-Fi will be available without charge.

A limited number of guest rooms have been reserved for Friday night at \$189 plus taxes until September 1

Pre-Program Activities	Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:00am	Registration and View Exhibits
7:30 am	<ul style="list-style-type: none"> • Opening Comments and Pre-Test
7:45 am	Hepatitis C: Update on Diagnostics <ul style="list-style-type: none"> • Short recap of key points from Pre-course lecture on viral hepatitis Hepatitis C: Update on Treatment <ul style="list-style-type: none"> • AASLD/IDSA Guidelines and Updates • Simplified Guidance • Case Studies 1 and 2 –New Case relevant to diagnosis and treatment of high-risk HCV patient
8:35am	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination The growing relationship between HBV and HDV
9:05 am	Anti-viral Therapies for HBV <ul style="list-style-type: none"> • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Reactivation of HBV

9:35 am	Industry Presentation #1 Break and View exhibits •
10:15 am	Delta Hepatitis and Hepatitis E Update • Worldwide perspective and promising research studies Real world outcome studies on HDV and HEV
10:45 am	End Stage Liver Disease: Recap and Clinical Case • A review of Pre-course lecture touching on staging, work-up and remedies for cirrhosis and the liver transplant process
11:15 am	Alcoholic Liver Disease • The growing prevalence of alcohol over-consumption and its impact on liver health • Warning signs and intervention in alcoholic hepatitis
11:45 am	Hepatocellular Carcinoma (HCC) • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery
12:15 pm	Luncheon and Industry Presentation #2
1:00pm	• Dessert and View Exhibits
1:10 pm	Hepatocellular Carcinoma: New Systemic Treatment Options • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 3– Diagnosis and Treatment of Hepatocellular Carcinoma
1:40 pm	SARS-COV-2 in Liver Disease • Effect of COVID on the liver and in cirrhotic patients • COVID-19 challenges for liver transplant recipients
2:10pm	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
2:45 pm	Break & View Exhibits
3:00 pm	NAFLD and NASH • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Fatty Liver Disease Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:35 pm	NASH Treatments in Practice and in Development • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy Drugs in clinical development for NASH
4:25 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:45 pm
Post-program activities	Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Overcoming barriers to liver health in special populations - 60 minutes

**Attendance
Policies**

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

**CME
Information**

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.

**Your
Seminar
Faculty**



SARO KHEMICIAN, MD

Saro Khemichian is a board certified transplant hepatologist who received his medical degree from University of Southern California Keck School of medicine. He then went on to complete his residency in Internal Medicine followed by Gastroenterology fellowship at LAC+USC Medical Center in Los Angeles. Dr. Khemichian then completed an extra year of training for Transplant Hepatology at Keck Medical Center of USC.

Dr. Khemichian's clinical interests include gastroenterology, hepatitis B, hepatitis C, chronic liver disease and liver transplantation. His research interests include complications of chronic liver disease, liver transplant, and treatment of hepatitis C infection.



SAMMY SAAB, MD, MPH

Sammy Saab is a Professor in the Departments of Internal Medicine and Surgery at the David Geffen School of Medicine. He is also Head of Outcomes Research in Hepatology at the Pflieger Liver Institute.

Dr. Saab received his BS, MD, and MPH from UCLA. He completed his residency in internal medicine at University of California at San Diego Medical Center and a fellowship in gastroenterology/hepatology at UCLA Center for Health Sciences. Dr. Saab is board certified in internal medicine, gastroenterology, and transplant hepatology. He has received honorary fellowships from the American Gastroenterology Association (AGAF), American College of Gastroenterology (FACG) and the American Association for the Study of Liver Diseases (FAASLD).



VINAY SUNDARAM, MD, MSc

Dr. Vinay Sundaram is an Associate Professor of Medicine and Director of Hepatology Outcomes Research at Cedars-Sinai Medical Center. He completed medical school at NYU school of medicine, followed by residency at the University of Virginia, gastroenterology fellowship at the University of Pittsburgh, and transplant hepatology fellowship at Beth Israel deaconess medical center. He is board certified in gastroenterology and transplant hepatology.

Dr. Sundaram has published more than 100 manuscripts and abstracts, including first authored papers in Gastroenterology, Hepatology, Journal of Hepatology, and Liver Transplantation. He is active in several professional societies including the American Association for the Study of Liver Disease and the American College of Gastroenterology.